When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.

Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

New weight-loss medications are reshaping U.S. healthcare by increasing diagnoses of obesity-related conditions and encouraging patients' engagement with health services. These drugs, including Wegovy ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Weight loss drugs, compounding, vitamin D, and AI all piqued readers’ interest — and sometimes, ire — this past year.

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...